1. Fucoidan modulates gut microbiota and immunity in Peyer's patches against inflammatory bowel disease.
- Author
-
Li JK, Veeraperumal S, Aweya JJ, Liu Y, and Cheong KL
- Subjects
- Animals, Mice, Mice, Inbred C57BL, Cytokines metabolism, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents chemistry, Disease Models, Animal, Male, Gastrointestinal Microbiome drug effects, Polysaccharides pharmacology, Polysaccharides chemistry, Peyer's Patches drug effects, Peyer's Patches immunology, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases immunology, Dextran Sulfate
- Abstract
Although fucoidan has potential use as an anti-inflammatory agent, the specific mechanisms by which it influences signaling and immunomodulatory pathways between gut microbiota and Peyer's patches remain unclear. Therefore, the aim of this study was to investigate the therapeutic potential of fucoidan in a dextran sulfate sodium (DSS)-induced mouse model of inflammatory bowel disease (IBD) by examining the effects on gut microbiota and the underlying anti-inflammatory mechanisms. Purified fucoidan, which upon characterization revealed structural fragments comprising →3)-β-D-Galp-(1→, →4)-α-L-Fucp-(1→, and →3)-α-L-Fucp-(1→ residues with a sulfation at position C2 was used. Treatment of the mice with fucoidan significantly alleviated the symptoms of IBD and restored the diversity of gut microbiota by enhancing the abundance of Bacteroidetes and reducing the proportion of Firmicutes. The administration of fucoidan also elevated levels of short-chain fatty acids while reducing the levels of pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ. Most importantly, fucoidan attenuated the expression of integrin α4β7/MAdCAM-1 and CCL25/CCR9, which are involved in homing intestinal lymphocytes within Peyer's patches. These findings indicate that fucoidan is a promising gut microbiota modulator and an anti-inflammatory agent for IBD., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF